How much funding has Newleos Therapeutics raised?

Newleos Therapeutics has raised $93.5M in total funding, most recently a Series A round.

Who are Newleos Therapeutics's investors?

Newleos Therapeutics's investors include Goldman Sachs Alternatives, Novo Holdings A/S, Longwood Fund, DCVC (Data Collab), Arkin Bio Ventures.

Where is Newleos Therapeutics headquartered?

Newleos Therapeutics is headquartered in Boston, United States.

What industry is Newleos Therapeutics in?

Newleos Therapeutics operates in Biotech, Healthcare.

How many employees does Newleos Therapeutics have?

Newleos Therapeutics has 11-50 employees.

Newleos Therapeutics

A new dawn for treatment of mental health conditions - Newleos

Boston, United States · $93.5M raised

Biotech

Healthcare

Headquarters: Boston
Employees: 11–50
Business Model: B2B
Website: newleos.com

Total Funding: $93.5M
Last Round: $93.5M Series AFeb 2025
Rounds: 1

About

Newleos Therapeutics is a Boston-based, clinical-stage biotechnology company co-founded by Longwood Fund and a team of experienced central nervous system (CNS) drug developers. The company is developing novel oral small-molecule treatments for neuropsychiatric disorders, including next-generation therapies designed to be safer than existing options, and has dosed its first patient in a Phase 2 program following a $93.5 million Series A financing.

Summary

Newleos Therapeutics is a Biotech company based in Boston, United States. It has raised $93.5M in total across 1 round, most recently a $93.5M Series A round in Feb 2025. Investors include Goldman Sachs Alternatives, Novo Holdings A/S and Longwood Fund.